Nishijima Soichiro, Sato Keiko, Onoue Tomohiro, Hashimoto Wataru, Shikano Mayumi
Graduate School of Pharmaceutical Sciences, Tokyo University of Science, Shinjuku-ku, Tokyo, Japan.
Clinical Science, Daiichi Sankyo Co. Ltd, Shinagawa-ku, Tokyo, Japan.
Future Oncol. 2025 May;21(12):1525-1535. doi: 10.1080/14796694.2025.2495543. Epub 2025 Apr 24.
The present study assessed the incidence of drug-induced interstitial lung disease (ILD) recurrence among breast cancer patients who underwent rechallenge with cancer-directed therapy.
MATERIALS & METHODS: Japanese insurance claims data and the Diagnosis Procedure Combination database (2009-2022) involving 81,601 patients were analyzed to evaluate 1,042 breast cancer patients who developed ILD. Of these, 566 patients underwent cancer-directed therapy rechallenge, and 42.1% of them were re-challenged with the same therapeutic regimen that caused the initial ILD.
ILD recurrence was observed in 18.9% of the patients, with a median recurrence time of 40 days. The drugs most commonly causing ILD were cytotoxic agents, and those most frequently used for rechallenge were cytotoxic agents.
A notable ILD recurrence rate was observed in breast cancer patients after a cancer-directed therapy rechallenge, highlighting the need for cautious treatment planning and personalised strategies to balance cancer control while mitigating ILD risk.
本研究评估了接受癌症导向治疗再激发的乳腺癌患者中药物性间质性肺疾病（ILD）复发的发生率。
分析了日本保险理赔数据和诊断程序组合数据库（2009 - 2022年），涉及81,601名患者，以评估1,042名发生ILD的乳腺癌患者。其中，566名患者接受了癌症导向治疗再激发，其中42.1%的患者接受了导致初始ILD的相同治疗方案的再激发。
18.9%的患者出现ILD复发，中位复发时间为40天。最常引起ILD的药物是细胞毒性药物，而再激发最常用的药物也是细胞毒性药物。
在接受癌症导向治疗再激发的乳腺癌患者中观察到显著的ILD复发率，突出了谨慎制定治疗计划和个性化策略以平衡癌症控制同时降低ILD风险的必要性。
